ReceptorBio signs licensing agreement with Telik

Preclinical testing has indicated that these insulin receptor activators, as single agents, lower glucose levels in models of diabetes. The compounds are active in the presence of sub-maximal levels of insulin, and do not cause hypoglycemia at the dose levels examined.

These compounds were identified through the application of Trap, Telik’s proprietary drug discovery technology. The agreement provides for payments related to regulatory milestones and royalties based on product sales.

Joseph Evans, co-founder and president of ReceptorBio, said: “ReceptorBio is very enthusiastic about gaining the opportunity to continue the development of the insulin receptor activator compounds discovered by Telik.

“These compounds have a unique mechanism of action directed against a validated drug target, the insulin receptor, and thus they represent a novel class of insulin sensitizers.”